Understanding Mechanism of Disease in Metastatic Castration Resistant Prostate Cancer (mCRPC)


DETAILS

April 16, 2023 | 1:30 pm 2:30 pm EDT

Spotlight Theater A | Presented by Pfizer Oncology


SPEAKERS

Presenter: Eleni Efstathiou, MD, PhD
Houston Methodist Cancer Center Genitourinary Medical Oncology Section Chief
Houston, Texas

Presenter: Alan H. Bryce, MD
Mayo Clinic
Chair – Division of Hematology/Oncology
Phoenix, Arizona


EVENT DESCRIPTION

Prostate cancer remains the most commonly diagnosed and second deadliest cancer in men. At initial diagnosis, most prostate cancer cases present with localized disease. However, approximately 10%–20% of prostate cancer patients develop metastatic castration-resistant prostate cancer (mCRPC) within 5−7 years of diagnosis, and in the U.S., in 2020, approximately 60-90 thousand cases of the three million prostate cancer cases were mCRPC. This Exhibitor Spotlight Theater will review the unmet needs and the current understanding of mechanism of disease for mCRPC. This Exhibitor Spotlight Theater is a promotional activity and is not approved for continuing education credit. The content of this Exhibitor Spotlight Theater and opinions expressed by presenters are those of the sponsor or presenter and are not of the American Association for Cancer Research® (AACR).

This Exhibitor Spotlight Theater is a promotional activity and is not approved for continuing education credit. The content of this Exhibitor Spotlight Theater and opinions expressed by presenters are those of the sponsor or presenter and are not of the American Association for Cancer Research® (AACR).